Clinical Trials Logo

Abortion, Spontaneous clinical trials

View clinical trials related to Abortion, Spontaneous.

Filter by:

NCT ID: NCT02303171 Recruiting - Clinical trials for Antiphospholipid Syndrome

Use of Warfarin After the First Trimester in Pregnant Women With APS

Start date: November 2014
Phase: Phase 4
Study type: Interventional

Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)

NCT ID: NCT02248376 Completed - Clinical trials for Uterine Synechiae After Scraping for Natural Miscarriage

Hyaluronic Acid and Uterine Synechiae

HYFACO
Start date: November 14, 2014
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to compare efficiency of a non-stick gel application after scraping surgery for natural miscarriage with no non-stick gel application after scraping surgery. Post-scraping uterine synechiae rate will be established at the diagnostical hysteroscopy 6-8 weeks after surgery.

NCT ID: NCT02201732 Completed - Clinical trials for Incomplete Miscarriage

Effectiveness of Hysteroscopy in the Treatment of Intrauterine Trophoblastic Retentions

HY-PER
Start date: November 5, 2014
Phase: N/A
Study type: Interventional

The purpose of this study of is to compare subsequent fertility rates between hysteroscopy and aspirative curettage in the surgical treatment of incomplete spontaneous abortion

NCT ID: NCT02184741 Completed - Clinical trials for Recurrent Miscarriage

A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

Start date: June 3, 2014
Phase: Phase 3
Study type: Interventional

The present survey was conducted to evaluate the efficacy and safety of GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison to placebo using a multicenter, double-blind, intergroup comparison method.

NCT ID: NCT02156063 Active, not recruiting - Clinical trials for Recurrent Pregnancy Loss

A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)

RESPONSE
Start date: June 2014
Phase: Phase 2
Study type: Interventional

This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous NT100 in pregnant women with a history of unexplained recurrent pregnancy loss. Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo.

NCT ID: NCT02145767 Completed - Preterm Birth Clinical Trials

Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial

Start date: December 2014
Phase: Phase 2
Study type: Interventional

Miscarriages and preterm births are common and serious events affecting women, families, and healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth is bleeding in the first trimester of pregnancy. Progesterone, a hormone that plays a key role during pregnancy, has been proposed as a possible medication to be used in pregnancy to prevent miscarriage and preterm birth among women who have bleeding in their first trimester of pregnancy. Unfortunately, unless sound clinical evidence is obtained through a clinical trial, whether or not progesterone can indeed prevent miscarriage and preterm birth remains uncertain and thus is not a recommended treatment in women with early pregnancy bleeding. The purpose of our study is to evaluate the effect of progesterone for the prevention of miscarriage and preterm birth among women with early pregnancy bleeding. We will carry out a clinical trial in which 850 women will be randomized to receive either progesterone supplementation (425 women) or a similarly appearing placebo (425 women) and the outcome of their pregnancy will be compared.

NCT ID: NCT02144064 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin

Start date: June 23, 2019
Phase: Phase 3
Study type: Interventional

Objective To determine maternal and fetal outcomes in women with Unexplained RPL managed with aspirin or unfractionated heparin (UFH) plus aspirin during pregnancy. Design: prospective clinical controlled study. Setting: high-risk pregnancy unit- Benha university hospital. Methods: Pregnant women with unexplained recurrent miscarriage attending high-risk pregnancy unit. 200 selected patients with previous unexplained recurrent miscarriage are divided into 2 groups: group A (n = 100) receive low-dose aspirin (81 mg once daily orally) plus heparin (5000 IU) every 12 h with the first positive pregnancy test while group B (n = 100) receive no thing . Main outcome measures: Maternal outcomes included thromboembolic and haemorrhagic complications and pregnancy-induced hypertension .Prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications

NCT ID: NCT02141555 Completed - Clinical trials for Spontaneous Abortion in First Trimester

Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss

Start date: August 2014
Phase: Phase 2/Phase 3
Study type: Interventional

First trimester miscarriages are common. When the failed pregnancy does not pass spontaneously on its own, it is called a missed abortion. There are several ways in which missed abortions are managed, one of which involves administering a medication called misoprostol which causes uterine contractions inducing expulsion of the failed pregnancy. Misoprostol can be administered in multiple ways but has been traditionally inserted vaginally when used for management of missed abortions. Some studies have shown that some women are not comfortable with vaginal insertion of misoprostol and prefer oral administration. Buccal misoprostol is a way of administering misoprostol by having the patients insert the tablets of misoprostol between their gum and cheek, letting it dissolve for 30 minutes, then swallowing the remaining remnants. Buccal misoprostol is used safely in medical abortion. In fact a study by Fjerstad et al (2009), found a decrease in infection rate for medical abortion when misoprostol administration was switched from vaginal to buccal route combined with routine administration of doxycycline. The efficacy of using buccal misoprostol to treat missed abortions has not been studied previously to the investigators' knowledge. In this pilot study, investigators aim to test the hypotheses that buccal misoprostol is equally effective as vaginal misoprostol in the medical management of early pregnancy loss. As secondary outcomes, investigators suspect that buccal misoprostol may be associated with higher rates of gastrointestinal side effect but that patient satisfaction will remain equally as high for buccal misoprostol as for vaginal misoprostol.

NCT ID: NCT02128685 Completed - Pregnancy Clinical Trials

Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage

Start date: March 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to determine whether the dydrogesterone therapy is associated with reduction in miscarriage in women with first trimester threatened miscarriage. The hypothesis is that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.

NCT ID: NCT02120378 Recruiting - Premature Birth Clinical Trials

Fetal Viability Estimation in Egypt

Start date: April 2014
Phase: N/A
Study type: Observational [Patient Registry]

Due to the discrepancy between the Egyptian and the conventional definition of miscarriage or live birth, there seemed to be a need for a study that ends up with reaching a definition for the mentioned terms. live birth is known to be for fetus born after 20 weeks or of weight more than 500 grams, while in Egypt, this is not applicable. basically the neonate has a chance of survival if the weight is more than 1000 grams or of gestational age more than 26 weeks.